Oricell Therapeutics closed a $110 million pre-IPO round to expand its global footprint and push forward its GPC3-targeted autologous CAR-T program, Ori-C101, toward registrational trials in hepatocellular carcinoma. The company said the funding will support broader clinical development and infrastructure as it prepares for pivotal-stage work. Ori-C101 has completed investigator-initiated testing and a registrational phase 1 study, and Oricell expects the asset to enter pivotal trials soon, targeting a tumor antigen (GPC3) highly expressed in liver cancers with limited expression in healthy tissue. The company’s portfolio also includes multiple earlier programs across solid tumors and hematologic malignancies. The round underscores investor appetite for next-wave solid-tumor cell therapy, including “armored” CAR-T approaches designed to navigate the immunosuppressive tumor microenvironment.